Submitted by Anonymous (not verified) on 13 March 2025 - 14:42
Human medicines European public assessment report (EPAR): Imraldi, adalimumab, Date of authorisation: 24/08/2017, Revision: 24, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Imraldi, adalimumab, Date of authorisation: 24/08/2017, Revision: 24, Status: Authorised